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Abstract: Nuclear receptors regulate the transcription of genes and various functions such 
as development, differentiation, homeostasis, and behavior by formation of complexes with 
ligand and co-activator. Recent findings have shown that agonists of a ligand may have a 
toxic effect on cellular/tissular function through improper activation of nuclear receptors. 
In this study, a simple assay system of hetero-complexes of three different molecules 
(estrogen receptor, ligand, and co-activator peptide) has been developed. This assay system 
employs functionalized gold nanoparticles (GNPs: 15 nm in diameter). The surfaces of the 
GNPs were modified by a 12- or 20-amino-acid peptide that contains the sequence of  
co-activator for activating nuclear receptor by an agonist ligand. Owing to the affinity of 
the peptide, the functionalized GNPs aggregate faster when the nuclear receptor and the 
agonist ligand are also present. The aggregation of GNPs can be identified by shifts in 
adsorption spectrum, which give information about the specificity of agonist ligands. 
Similarly, this spectrum shift can measure concentration of known agonist ligand. This 
simple agonist screening will be employed as high through-put analysis (HTA) in the 
discovery of drugs that act through nuclear receptors. 
Keywords:  estrogen receptor; gold nanoparticles; high-throughput screening; SRC1 
peptide 
 
OPEN ACCESSSensors 2012, 12                                       
 
 
4953
1. Introduction 
The development of clinical drugs is also known as drug discovery because most of the lead 
substances have been found from either natural sources or huge collections of compounds. Finding a 
lead compound that can be a starting compound for subsequent screening is generally a time-consuming 
process. The first step of the investigation is key for the successful development of a clinical drug [1]. 
Hence, high-through-put screening (HTS) in the drug discovery process could be an effective and 
time-saving procedure for the successful identification of lead-substances because of its efficiency and 
low-cost for the development of clinical drugs. 
In recent years, nuclear receptors have received much attention as molecular targets of clinical 
drugs being developed against human diseases. Nuclear receptors are transcription factors that mediate 
the expression of hormones-responsive genes [2,3]. The transcriptional responses depend on the 
specific type of nuclear receptor, and they play important roles in embryonic development, 
differentiation, reproduction, and metabolic homeostasis [4]. As two examples, estrogen receptor (ER) 
and androgen receptor (AR) are well-known nuclear receptors that are strongly involved in breast 
cancer and prostate cancer, respectively [5,6]. Tamoxifen is well known as an antagonist of ER, and is 
currently used for the treatment of ER-positive breast cancer [5]. Peroxisome proliferator-activated 
receptors (PPARs) are directly implicated in lipid transport and metabolism [7]. In particular, PPARγ 
agonists are used for their potent antidiabetic effects. In addition, the thiazolidinediones are a class of 
medicines used in the treatment of diabetes mellitus type 2 [8]. 
In the recent development of ligand-based drugs, in vitro and in vivo screening methods have been 
utilized for the identification of lead-substances. The simplest assays are radio-ligand competition 
binding assays [9]. These assays can only confirm the binding affinity between a ligand and a nuclear 
receptor. However, the assay cannot identify ligand characteristics, such as agonist/antagonist activity. 
In order to evaluate a ligand’s activity, various types of methods have been developed. In other words, 
it is expected that HTS of various NR are developed. 
 For example, surface plasmon spectroscopy (SPR) and quartz crystal microbalance (QCM) have 
been well used for affinity sensing of biomolecules in recent years [10,11]. By employing these 
methods, it is possible to identify a ligand’s mode of action. However, these approaches are difficult to 
utilize for HTS to analyze many samples simultaneously. 
 Alternatively, reporter gene assays based on stably transfected cell lines are a popular type of  
in vivo assay to evaluate transcriptional activity [12]. This method provides the most specific and 
responsive means to screen substances for potential activity. However, it is not appropriate for HTS for 
the identification of lead-substances in drug discovery, because the assay requires more time for 
evaluation than the above in vitro methods. 
In this study, we have focused on gold nanoparticles (GNPs) as a signal transducer that enables the 
affinity interaction between a nuclear receptor and agonist ligands to be detected by shifts in the 
absorption spectrum. GNPs have unique optical, electrical, and magnetic properties [13]. In particular, 
the optical spectra of GNPs show a localized surface plasmon band in the region of 520–550 nm. The 
absorption spectrum of GNPs changes drastically when several particles aggregated [14]. Various 
types of GNPs based sensors (DNA, antibody, polymer) [15–17] have been developed to take 
advantage of this property. Sensors 2012, 12                                       
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In order to discover agonists of nuclear receptors, co-activator proteins have been utilized to analyze 
the affinity of ligand-activated receptors. Steroid-receptor co-activator-1 (SRC1) is a ligand-inducible 
transcription factor of the steroid-hormone receptor superfamily. Ligand-activated steroid-hormone 
receptor forms a complex with SRC-1, and the complex enhances transcriptional activity. LXXLL 
motifs of co-activators are known to be essential for interaction with ligand-activated nuclear   
receptors [18]. 
In this manuscript, we report and discuss a smart assay method using functionalized (molecularly 
modified) GNPs for ligand screening of human estrogen receptor alpha subtype (hERα). A synthetic 
peptide containing the LXXLL motif of SRC-1 can be employed as a molecular-recognition element of 
ligand-activated nuclear receptors. This colloidal sensor was constructed to utilize a modified SRC-1 
peptide on the GNP surface for measurement purposes. When ligand-activated hERα forms complexes 
with functional GNPs, the absorption spectrum of the solution is changed by a decrease of the colloidal 
stability in the solvent. In this study, we have developed and demonstrated the utilization of this 
phenomenon for a colorimetric biosensor, and then discussed its application for HTS of nuclear 
receptor ligands in drug discovery. 
2. Experimental Section  
2.1. Chemicals 
Gold nanoparticles (15 nm in diameter, 0.0065 wt%) were purchased from Tanaka Kikinzoku 
Kogyo K.K. (Tokyo, Japan). Purified recombinant human estrogen receptors (hERα), 17β-estradiol, 
and tamoxifen citrate were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). 
Methoxytrityl-S-dPEG4 acid was purchased from Quanta Biodesign (Boston, MA, USA). 
2.2. Synthesis of Functional Peptides 
Functional peptide-1 (FP1: its sequence is shown in Table 1) was synthesized by a solid-phase 
method using fluorenemethyloxycarbonyl (Fmoc) chemistry starting from H-Asp(OTBu)-Trt(2-Cl) 
resin (0.25 mmol·g
−1). The removal of the Fmoc group was carried out by treatment with 20% 
piperidine solution in N-methylpyrrolidone (NMP) for 30 min. The condensation reaction was 
mediated by 2-(1H-benzotriazole-1-yl)-1,1,3,3,-tetramethyluronium hexafluorophosphate (HBTU),   
1-hydroxybenzotriazole hydrate and diisopropylethylamine in the same amounts (3 eq., 0.66 mmol) in 
NMP using a standard protocol [19]. The functional peptide was cleaved from the resin and the 
protecting group by treatment with a mixture of trifluoroacetic acid, ethanedithiol, thioanisole, water 
and phenol (80:2.5:5:5:7.5 v/v; 10 mL) for 4 h in an ice bath. After filtration, trifluoroacetic acid 
(TFA) was evaporated, and the peptides were precipitated by the addition of diethyl ether, centrifuged, 
resuspended in diethyl ether, and then dried. The desired peptides were purified by high-performance 
liquid chromatography (HPLC) using an XTerra Prep MS C18 column. The molecular mass of the 
purified peptide was confirmed by matrix-assisted laser desorption ionization-time of flight-mass 
spectroscopy (MALDI TOFMS). Similarly, functional peptide-2 (FP2: This sequence is shown in 
Table 1) was synthesized by a solid-phase method and checked the molecular mass using LCMS. 
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Table 1. Designed sequences of functional peptides. 
Peptides  Designed Sequences 
Functional peptide 1(FP1) CLTERHKILHRLLQEGSPSD 
Functional peptide 2(FP2) Thiol-PEG4-RHKILHRLLQED 
2.3. Affinity Assay Between Synthesized Functional Peptide and hERα on Gold Plate 
The functional peptides were modified on a gold plate through thiol for 1 h. After the modification, 
the functional peptides were confirmed to have formed complexes with ERα using EnBio RCAS for 
ERα (Fujikura Kasei Co., Ltd. Tokyo, Japan) [20]. 
2.4. Binding of Modified Functional Peptides with Gold Nanoparticles 
FP1 at 5 μg/mL and FP2 750 μg/mL were prepared with 10 mM citrate buffer (pH 6.0). These 
solutions were mixed in a 1:1 ratio with GNPs (15 nm) and incubated for 1 h. To remove free 
functional peptides, the particle solutions were centrifuged (~14,000 g) for 20 min and the supernatant 
was removed and replaced with hERα reaction buffer (10 mM HEPES (pH 7.4), 200 mM NaCl, 10% 
glycerol, 0.05% Tween 20). Characterization of particle size and zeta potential were assayed by 
Zetasizer Nano ZS (MALVERN, Malvern, UK). 
2.5. UV-Vis Spectra of GNP Measurement 
GNPs were added to 45 nM of hERα and with or without ligand (E2 or tamoxifen).The mix 
solution incubated at 25 °C. Then the absorbance spectrums of solution were measured using 
Ultrospec 3300 pro (GE Healthcare, Little Chalfont, UK) at each time point. 
3. Results and Discussion 
Figure 1 shows a schematic view of the agonist ligand assay for a nuclear receptor with GNPs. 
Functional peptide-modified GNPs (GNP-FP) are dispersed in aqueous solution by the action of the 
modified functional peptides. In this study, hERα is employed as a model target molecule (analyte). 
GNP-FP is mixed with hERα activated by an agonistic ligand in advance. Then, the hERα forms a 
complex with the functional peptide on the GNP surface. As a result, GNP-FP aggregates and its 
absorption spectrum is changed. On the other hand, the antagonistic ligand cannot activate hERα and 
thus GNP-FP does not aggregate in this case. In addition, its absorption spectrum is not changed 
because GNP-FP cannot form a complex with antagonistic ligand binding hERα.  
As shown in Table 1, FP1 and FP2 were designed on the basis of SRC-1 NR box II within the 
LXXLL motif, which can form a specific complex with activated hERα[18]. FP1 consists of 20 amino 
acid peptide that can bind covalently with gold through the N-terminal cysteine in the peptide. FP2 is 
composed of the following functional units: (1) polyethylene glycol (PEG) that was introduced in 
order to suppress unspecific adsorption of hydrophobic peptide to the nanoparticle surface (thiol was 
also tagged to the N-terminal of the PEG for binding to GNPs); and (2) the 12-mer peptide, which is 
also designed on SRC-1 NR box II to form a specific complex with hERα activated by agonist   Sensors 2012, 12                                       
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ligand. Above the design concept of functional peptide, we expect that FP2 is superior to FP1 as a  
molecular-recognition element of functionalized GNPs. 
Figure 1. Schematic illustration of detection of ligand activity using modified functional 
peptide-associated GNPs. 
 
First, we investigated complex formation between functional peptide and hERα with or without 
ligand, as shown in Figure 2. This figure shows the affinity assay of synthesized peptides with hERα 
activated by agonist ligand using the affinity assay kit. The agonist ligand (E2) sample shows a higher 
level of optical density than the other samples [with no ligand or antagonist ligand (tamoxifen)] and 
shows a significant difference in this regard compared with the other samples. Accordingly, the 
synthesized functional peptides were expected to have ligand selectivity for hERα and form a specific 
complex with estrogen receptor. 
Figure 2. Confirmation of the presence of complex between synthesized functional peptide 
and hERα on gold plate (n = 3): (a) modification of FP1; (b) modification of FP2. 
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To determine aggregation by the specific formation of complexes with hERα on GNPs in a   
ligand-dependent manner, we obtained the spectra of GNP-FP1 and 2 at 30 min after the addition of 
hERα and ligands (Figure 5). In the case of GNP-FP1, the change of spectrum was dependent on 
ligand at 30 min (Figure 5(A)), but at 2 h (data not shown), the spectrum of GNP-FP1 was shifted to 
the right in the case of E2 compared with the other ligands. On the other hand, in the case of GNP-FP2, 
the spectra were already shifted to the right compared to the other ligands at 30 min already (Figure 5(B)). 
Both results show that the sample of agonist ligand (E2) causes a larger change in the spectrum than 
the other ligand samples. These results indicate that GNP-FP1 and 2 can be used to estimate ERα 
activity in a ligand-dependent manner. Namely, it is possible for agonist activity to be measured by 
determining the rate of aggregation. In addition, GNP-FP2 can be used to determine the agonist 
activity of hERα faster than GNP-FP1.  
Figure 5. UV-Vis Spectra of GNPs in the presence of (a) control (without hERα and 
ligand); (b) hERα; (c) hERα and E2; and (d) hERα and tamoxifen at 30 min (addition of 
substances to be examined). (A) Modification of FP1; (B) modification of FP2. 
 
(A)           (B) 
Figure 6. Aggregation kinetics of GNP-FP2 in the presence of a—control (without 
hERα and ligand); b—hERα; c—hERα and E2; and d—hERα and tamoxifen. 
 
To easily estimate ligand activity of hERα from spectrum data, we defined the ratio of absorbances 
at 660 nm/535 nm as the sensor response. 535 nm is wavelength of adsorption maximum 
corresponding to both GNP-FP1 and 2. For its part, 660 nm is value of maximum in differential 
spectrum between aggregation of before and after. The sensor response is recorded over time, which 
enables estimation of the ligand activity (Figure 6). From sensor response data, E2 (agonist ligand) was 
shown to enable faster aggregation of GNP than the other samples. In contrast, tamoxifen (antagonist Sensors 2012, 12                                       
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ligand) produced a result similar to the case without a ligand because tamoxifen bound to 
ERα prevents formation of a complex with co-activator. Briefly, the sensor responses indicate that the 
specific formation of a complex on the GNP surface is dependent on the ligand and can be used to 
estimate agonist activity of the ligand. 
Using GNP-FP2, we attempted to determine E2 concentrations by the sensor response, which was 
measured 30 min after the reaction of activated hERα with E2 (Figure 7). Figure 7 shows relation 
between E2 concentration and sensor response. The plots clearly showed sigmoid curve. Below 0.5 
nM, the sensor response is not enough to determine E2 concentration. However, between 0.5 nM to 25 
nM, the sensor response is linear against E2 concentration. In the higher concentration than 25 nM, the 
response reachs a plateau. This finding showed why hERα concentration is constant 45 nM in every 
concentration of the ligand. Therefore, the plateau of response is between approximately 25 nM to  
50 nM. because hERα and E2 were reactive at a ratio of 1:1.  
Figure 7. Degree of aggregation in term of E2 concentration with GNP-FP2 (n = 3). 
 
4. Conclusions 
In this study, using GNP-FP, we succeeded in detecting specific formation of complexes with 
hERα, functional peptide and ligands. The three-molecule hetero-complex assay is based on the in situ 
function of hERα. The system can recognize ligands that are inappropriate for drug development of 
nuclear receptors by a simple method. It can be systemized with HTS in good reproducibility. The 
advantages of this method are as follows: (1) hERα and ligands do not require labeling; and (2) the 
substance to be examined can be screened as an agonist in 30 min. Given these advantages, this 
method is expected to be applicable for the first stage of screening in drug discovery. In this study, 
hERα was used as a model for agonistic ligand screening of nuclear receptor. However, it is possible 
to expand this system for other nuclear receptors. Moreover, it is expected that the method can be used 
to estimate the level of agonist activity on a nuclear receptor and to determine the concentration of 
agonist ligand by sensor response. 
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